EX-10.5 22 mar1303_ex10-05.txt EXHIBIT 10.5 ims 12th March 2003 Adrian Kemp AstraZeneca plc Legal & Secretary's Department Room 3.10, Stanhope Gate 15 Stanhope Gate London W1K 1LN Dear Adrian, IMS Data Disclosure for Annual Report In connection with AstraZeneca's anticipated filing of certain registration statements IMS HEALTH hereby authorizes you to refer to IMS HEALTH and Certain pharmaceutical industry data derived by IMS HEALTH, as identified on the pages annexed hereto as Exhibit A, a selection of pages from AstraZeneca's Annual Report for the fiscal year ended 2002 (the "Annual Report", which is incorporated by reference in the registration statement No. 33-83774 on Form F-3, for AstraZencca group and Zeneca Wilmington Inc., and in the registration statements No. 333-09060, No. 333-09062, No. 333-65362, No. 33-65366, No. 333-12310, No. 333-12426, No. 333-12428, No. 333-13328 and No. 333-13918 on Form S-8 for AstraZeneca Plc. A copy of the relevant pages of the Annual Report has been provided to IMS HEALTH. Our authorization is subject to your acknowledgment and agreement that: 1) IMS HEALTH has not been provided with a full copy of the draft Annual Report but only a very limited number of pages from the documents as indicated above; 2) IMS HEALTH has not undertaken an independent review of the information disclosed in the Annual Report other than to discuss our observations as to the accuracy of the information relating to IMS HEALTH and certain pharmaceutical industry data derived by IMS HEALTH; and 3) AstraZeneca accepts full responsibility for the disclosure of all information and data, including that relating to IMS HEALTH, set forth in the Annual Report as filed with the SEC and agrees to indemnify IMS HEALTH from any third party claims that may arise therefrom. Please indicate your agreement to the foregoing by signing in the space indicated below. Our authorisation will not become effective until accepted and agreed by AstraZeneca. Very truly yours, /s/ Paul Jenner Paul Jenner, Director Communications and Marketing Services For and on behalf of IMS HEALTH IMS Health Tel +44(0)20 7393-5000 IMS A.G. registered & 7 Harewood Avenue Fax+44(0)20 7393-5900 incorporated with London NWI 6JB limited liability in United Kingdom Zug, Switzerland, registered as a branch in England, Ref. No. BR 1589, Swiss address Dorfplatz 4, 6330 CHAM. ims ACCEPTED AND AGREED THIS 20TH DAY OF MARCH 2003: AstraZeneca By: /s/ Adrian C N Kemp ------------------------------------ Name: Adrian C N Kemp ---------------------------------- Title: Assistant Secretary ---------------------------------- Appendix A: Selection of pages in Annual Report IMS Health Tel +44(0)20 7393-5000 IMS A.G. registered & 7 Harewood Avenue Fax+44(0)20 7393-5900 incorporated with London NWI 6JB limited liability in United Kingdom Zug, Switzerland, registered as a branch in England, Ref. No. BR 1589, Swiss address Dorfplatz 4, 6330 CHAM. EXHIBIT A Annotations from Final version Feb 20 2003 IMS.pdf Page 3 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:45:12 Nexium NRX and TRX US Page 7 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date; 2003-02-20 13:46:21 Seroquel US (N5A1); Atacand global (Excl Japan) C9C+C9D Page 10 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:46:59 US market size and growth Page 12 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:47:55 Global market (32 countries) growth: Selected markets share and growth Annotation 2: Label: BaseInstaller: Date: 2003-02-20 13:48:50 Top5 and top10 corporations share of global Page 13 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:49:18 A2B2 market size Annotation 2; Label: BaseInstaller; Date: 2003-02-20 13:51:06 US - Nexium overtake Losec RX; Nexium global and US share of A2B2 Annotation 3; Label: BaseInstaller; Date: 2003-02-20 13:51:23 Losec US and global share Page 14 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 13:56:14 CV treatment: C, B1, B2, A8A, A10 Annotation 2; Label; BaseInstaller; Date: 2003-02-20 13:57:05 Atacand, C9C+C9D 31 countries Annotation 3; Label: BaseInstaller; Date: 2003-02-20 13:58:05 Atacand C9C+C9D Annotation 4; Label: BaseInstaller; Date: 2003-02-20 14:01:35 Intprd Betaloc Annotation 5; Label: BaseInstaller; Date: 2003-02-20 14:02:59 Zestril family: Zestril, Zestoretic, (C9A+C9B) Annotation 6; Label: BaseInstaller; Date: 2003-02-20 14:04:12 Statin market: ClOAl Page 15 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:07:10 Cancer therapy market: L1+L2 Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:09:09 Casodex; Antiandrogens L2B2 Annotation 3; Label: BaseInstaller; Date: 2003-02-20 14:09:59 Arimidex; Aromatase inhib. L2B3 Page 16 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:17:54 Thinfection world market is an AstraZeneca estimation Page 17 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:19:16 Total R-class Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:20:45 Symbicort: R3f1 Annotation 3; Label: BaseInstaller; Date: 2003-02-20 14:22:49 Pulmicort Respules. US NPA data Annotation 4; Label: BaseInstaller; Date: 2003-02-20 14:23:21 Oxis. R3A3 Annotation 5; Label: BaseInstaller; Date: 2003-02-20 14:24:40 Rhinocort Aqua. RX % of R1A1 Page 18 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:27:15 CNS therapies: N2C, N3A, N4A, N5, N6, N7 Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:53:09 Seroquel, Antipsychotic market N5A Annotation 3; Label: BaseInstaller; Date: 2003-02-20 14:54:03 Zomig. Share of N2C Page 19 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 14:57:32 Pain control Market, AZ defined: M1A, M2A, Narcotics, Weak Opioids, Simple analgetics, N2C, Neurontin (60% US, 30% EU and 10% RoW) Annotation 2; Label: BaseInstaller; Date: 2003-02-20 14:58:17 Anaesthetic market: N1 Annotation 3; Label: BaseInstaller; Date: 2003-02-20 15:19:59 Diprivan, N1A Page 20 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 15:22:02 Nexium. Share of A2B2 TRX Annotation 2; Label: BaseInstaller; Date: 2003-02-20 15:36:51 Zestril TRX share of C9A Annotation 3; Label: BaseInstaller; Date: 2003-02-20 15:38:51 Toprol-XI TRX share of C7A Annotation 4; Label: BaseInstaller; Date: 2003-02-20 15:40:52 Casodex: L2B2 Page 21 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 15:45:37 Oncology = L1+L2 Annotation 2; Label: BaseInstaller; Date: 2003-02-20 15:47:42 All countries: Nexium share of A2B2; Symbicort share of R3F1 Page 22 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 15:49:18 Casodex share of L2B2 Annotation 2; Label: BaseInstaller; Date: 2003-02-20 15:49:52 Seroquel share of N5A1 Page 24 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:28:05 Nexium share of A2B2 Page 25 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:26:28 Symbicort share of R3F1 Page 26 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:29:18 Seroquel share of N5A1 Annotation 2; Label: BaseInstaller; Date: 2003-02-20 16:30:06 Zomig share of N2C1 Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:55:57 Pages 34-40 not attached in this document. Pages 40-43 from last year's Financial Review, according to US requirements. Rest of Annual report no market data included. Page 27 -------------------------------------------------------------------------------- Annotation 1; Label: BaseInstaller; Date: 2003-02-20 16:41:37 Pages 56 to 113 not attached in this document/EJ